This study evaluated the effectiveness and safety of TAS-102 (Lonsurf; trifluridine-tipiracil) plus Yttrium-90 (Y-90) radioembolization (RE) for patients with colorectal cancer liver metastasis (CRLM) who are unresponsive to chemotherapy. The data showed that TAS-102 plus RE was safe and effective in these patients.

This study evaluated the effectiveness and safety of panitumumab (Vectibix) rechallenge when added to maintenance therapy with FOLFIRI {fluorouracil (FU; Adrucil), folinic acid (FA; Leucovorin), irinotecan (Camptosar)} in patients with RAS wild-type metastatic colorectal cancer (mCRC). The data showed that maintenance therapy with panitumumab plus FOLFIRI was effective with manageable side effects in these patients.

This study evaluated the effectiveness of chemotherapy before surgery for the treatment of patients with resectable colorectal cancer liver metastasis (CRLM). The data showed that the addition of chemotherapy before surgery significantly improved disease-free survival (survival without any signs or symptoms of cancer) but not the overall survival in these patients.

This study evaluated the health-related quality of life (HR-QoL) outcomes of second-line chemotherapy combined with either bevacizumab (Avastin) or with cetuximab (Erbitux) in patients with advanced colorectal cancer with wild-type KRAS. This study concluded that the HR-QoL outcomes were similar with both treatments in these patients.

This study compared the effectiveness of TAS-102 (Lonsurf; trifluridine-tipiracil) versus regorafenib (Stivarga) for the treatment of patients with metastatic colorectal cancer (mCRC). The data showed that TAS-102 had better oncologic outcomes than regorafenib in these patients.

This study evaluated the effectiveness and safety of adding oxaliplatin (Eloxatin; 3 months vs 6 months) to 6 months of fluoropyrimidine therapy such as 5-Fluorouracil (Adrucil) or capecitabine (Xeloda) as adjuvant (treatment after surgery) treatment in patients with stage II or III colon cancer. The data showed that adding 3 months of oxaliplatin to 6 months of fluoropyrimidine treatment could be considered an alternative adjuvant treatment option in patients treated with capecitabine plus oxaliplatin.

This study evaluated the effectiveness and safety of microwave ablation (MWA) therapy for the treatment of lung metastases in patients with colorectal cancer (CRC). The data showed that MWA therapy might be a safe and effective option for these patients.

This study evaluated the effectiveness of chemotherapy given before surgery (neoadjuvant chemotherapy; NAC) for the treatment of patients with colorectal cancer liver metastasis (CRLM) at high risk. The data showed that NAC improved the overall survival of these patients.

This study evaluated the effectiveness and safety of the combination of trifluridine-tipiracil (Lonsurf) and bevacizumab (Avastin) in patients with unresponsive (refractory) metastatic colorectal cancer (mCRC) in a real-world setting. The main finding was that trifluridine-tipiracil plus bevacizumab was safe and effective in patients with mCRC in a real-world setting.

The study evaluated the effectiveness of massage therapy for chemotherapy-induced peripheral neuropathy (CPIN) in patients with breast and gastrointestinal (GI) cancer. The main finding of the study was that intensive massage therapy 3 times a week showed promising results in these patients.